Patient-derived xenograft (PDX) models of BRCA-deficient and BRCA-like ovarian tumors reflect clinical responses to PARP inhibition. (December 2016) - Davies, A.; Hou, J.; Shih, L.M.; Wright, J.D.; Ciznadija, D.; Katz, A.; Sidransky, D.